Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In the present study, we investigated the treatment efficacy and clinical outcomes of botulinum neurotoxin-A (BoNT-A) administered for longer than 5 years to patients with essential blepharospasm. Methods: We retrospectively reviewed 19 patients (male : female = 8 : 11) diagnosed with essential blepharospasmbetween March 2006 and July 2016 who underwent BoNT-A injections for over 5 years and were followed. Efficacy of 297 injections of Botox (n = 162), Meditoxin (n = 75), Hugel-tox (n = 40), or Dysport (n = 20)was based on the symptom improvement score at the final injection (-1, worse; 0, same; 1, better). Injectiondose (botox unit), duration of efficacy (months), and adverse events were also investigated. Results: Based on product type, significant differences in patient age (59.3 ± 9.8 years), disease period (5.0 ±5.4 years), number of botulinum neurotoxin injections before visiting our clinic (1.6 ± 2.6), and follow-up period(7.2 ± 1.6 years) were not observed. Treatment efficacy score and injection dose of repetitive injections were0.1 ± 0.5 and 39.1 ± 4.0 units, respectively, and did not show significant differences with repeated injections. Duration of response was 5.9 ± 5.4 months, but this significantly decreased as the injections were repeated (p< 0.01). Among the 297 injections, adverse events occurred 12 times (4.0%) with no severe sequelae. Conclusions: In this study, we showed that repetitive, long-term BoNT-A injections are considered a stableand effective treatment for essential blepharospasm in terms of consistent injection dose and maintenanceof treatment efficacy. However, the duration of long-term efficacy could be decreased in patients injectedrepetitively.
Abstract
In the present study, we investigated the treatment efficacy and clinical outcomes of botulinum neurotoxin-A (BoNT-A) administered for longer than 5 years to patients with essential blepharospasm. Methods: We retrospectively reviewed 19 patients (male : female = 8 : 11) diagnosed with essential blepharospasmbetween March 2006 and July 2016 who underwent BoNT-A injections for over 5 years and were followed. Efficacy of 297 injections of Botox (n = 162), Meditoxin (n = 75), Hugel-tox (n = 40), or Dysport (n = 20)was based on the symptom improvement score at the final injection (-1, worse; 0, same; 1, better). Injectiondose (botox unit), duration of efficacy (months), and adverse events were also investigated. Results: Based on product type, significant differences in patient age (59.3 ± 9.8 years), disease period (5.0 ±5.4 years), number of botulinum neurotoxin injections before visiting our clinic (1.6 ± 2.6), and follow-up period(7.2 ± 1.6 years) were not observed. Treatment efficacy score and injection dose of repetitive injections were0.1 ± 0.5 and 39.1 ± 4.0 units, respectively, and did not show significant differences with repeated injections. Duration of response was 5.9 ± 5.4 months, but this significantly decreased as the injections were repeated (p< 0.01). Among the 297 injections, adverse events occurred 12 times (4.0%) with no severe sequelae. Conclusions: In this study, we showed that repetitive, long-term BoNT-A injections are considered a stableand effective treatment for essential blepharospasm in terms of consistent injection dose and maintenanceof treatment efficacy. However, the duration of long-term efficacy could be decreased in patients injectedrepetitively.
참고문헌 (13)
- Kenney C, "Botulinum toxin in the treatment of blepharospasm and hemifacial spasm", J Neural Transm (Vienna), 115, pp.585~591 (2008)[DOI]
- Naumann M, "Safety and efficacy of botulinum toxin type A following long-term use", Eur J Neurol, 13(Suppl 4), pp.35~40 (2006)[DOI]
- 성영제, "Clinical Outcomes of Individualized Botulinum Neurotoxin Type A Injection Techniques in Patients with Essential Blepharospasm", Korean Journal of Ophthalmology, 29(2), pp.115~120 (2015), 대한안과학회
- Scott AB, "Botulinum A toxin injection as a treatment for blepharospasm", Arch Ophthalmol, 103, pp.347~350 (1985)[DOI]
- Dutton JJ, "Botulinum toxin in ophthalmology", Surv Ophthalmol, 52, pp.13~31 (2007)[DOI]
- Sampaio C, "DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A (Dysport a nd Botox) a ssuming a ratio o f 4:1", Mov Disord, 12, pp.1013~1018 (1997)[DOI]
- Rieder CR, "A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm", Clin Neuropharmacol, 30, pp.39~42 (2007)[DOI]
- Pagan FL, "A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin: a new botulinum neurotoxin A", Parkinsonism Relat Disord, 18, pp.441~445 (2012)[DOI]
- 신재호, "본태눈꺼풀연축 환자에서 디스포트와 보톡스 효과 비교", 대한안과학회지, 50(3), pp.331~335 (2009), 대한안과학회
- 윤진숙, "Double-Blind, Randomized, Comparative Study of Meditoxin® Versus Botox® in the Treatment of Essential Blepharospasm", Korean Journal of Ophthalmology, 23(3), pp.137~141 (2009), 대한안과학회
- Ababneh OH, "Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm", Clin Exp Ophthalmol, 42, pp.254~261 (2014)[DOI]
- Ramirez-Castaneda J, "Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up", Toxicon, 90, pp.344~348 (2014)[DOI]
- Czyz CN, "Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome", Am J Ophthalmol, 156, pp.173~177 (2013)[DOI]